<DOC>
	<DOCNO>NCT02602704</DOCNO>
	<brief_summary>- The purpose study study effectiveness bazedoxifene prevent loss bone mineral density ( BMD ) trabecular bone score ( TBS ) , fracture postmenopausal rheumatoid arthritis ( RA ) patient receive long-term GCs . - This randomize , control , open-label extension study 48 56 week . At study entry , patient receive elemental calcium ( 1200 mg daily ) vitamin D ( 800 IU daily ) randomize block two receive either bazedoxifene ( 20 mg/day ) none .</brief_summary>
	<brief_title>Effectiveness Bazedoxifene Prevention Glucocorticoid-induced Bone Loss RA Patients</brief_title>
	<detailed_description />
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<mesh_term>Vitamins</mesh_term>
	<mesh_term>Vitamin D</mesh_term>
	<mesh_term>Bazedoxifene</mesh_term>
	<mesh_term>Calcium , Dietary</mesh_term>
	<mesh_term>Glucocorticoids</mesh_term>
	<criteria>Female RA patient ≥ 45 year old selfreported postmenopausal ≥12 month prior hysterectomy bilateral oophorectomy . Female patient ≥ 55 year old prior hysterectomy without oophorectomy unilateral oophorectomy . Having receive low moderate dose glucocorticoid ( prednisone ≤7.5 mg/day equivalent ) ≥3 month prior entry . ( When take glucocorticoid PRN , prednisone ≥1mg/day average . ) Patients expect glucocorticoid treatment 3 month entry . Patients osteopenic mean lumbar spine ( LS ; L1L4 ) femoral neck bone mineral density ( BMD ; 1 &lt; Tscore &lt; 2.5 ) Patients provide write consent participate study . Patients condition may interfere evaluation spinal hip osteoporosis DXA two vertebral ( L1L4 ) fracture vertebral deformity Patients hypercoagulability risk factor history deep vein thrombosis pulmonary embolism History allergic reaction intolerance bazedoxifene SERM Patients receive bisphosphonates , parathyroid hormone , SERMs , anticonvulsants therapy within 6 month prior entry Patients know bone disorder osteomalacia , renal osteodystrophy hyperparathyroidism Patients undiagnosed uterine bleeding Patients severe renal impairment creatinine clearance &lt; 30ml/min</criteria>
	<gender>Female</gender>
	<minimum_age>45 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>